2012 Third-quarter Revenue

• Revenue surged 17.1% in the third quarter and 17.2% over the first nine months of the year
• Growth in Africa (80% of revenue) came to 23% (in the third quarter and over the first nine months of the year)...

Download the slideshow: 2012 Third-quarter Revenue.

In a statement, Alain Viry, Chairman of CFAO's Management Board said:

«CFAO's excellent performances in Africa – up 23% – confirm the strength of the Group's strategy and its leading position in its businesses.

Two major acquisitions for the future development of Eurapharma were carried out recently: one in Nigeria, the main pharmaceutical market in Sub-Saharan Africa, and the other with Missionpharma, the world leader in medical kits.

The change in primary shareholder which is currently underway with the acquisition by Toyota Tsusho Corporation (TTC) of an interest in CFAO marks the beginning of a new period which will see not only the continuation of our current strategy, but also new development opportunities in CFAO's markets. This is the spirit of TTC's publicly expressed intentions in relation to its investment in CFAO.

Based on the current market climate, we can look forward to the final quarter of 2012 with confidence and confirm our aim to achieve revenue growth in excess of 12% and a recurring operating margin of above 8.0% in 2012.»